Shield Therapeutics PLC
LSE:STX
Income Statement
Earnings Waterfall
Shield Therapeutics PLC
Income Statement
Shield Therapeutics PLC
| Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
4
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
+27%
|
0
-34%
|
1
+215%
|
1
+55%
|
12
+1 100%
|
12
-1%
|
1
-94%
|
9
+1 181%
|
10
+13%
|
2
-81%
|
2
-22%
|
4
+140%
|
5
+51%
|
7
+31%
|
13
+81%
|
21
+60%
|
32
+54%
|
41
+29%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(4)
|
(9)
|
(14)
|
(17)
|
(21)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
+7%
|
0
-39%
|
0
+289%
|
1
+54%
|
12
+1 459%
|
11
-2%
|
0
-98%
|
8
+3 329%
|
9
+13%
|
1
-87%
|
1
-55%
|
2
+261%
|
2
+26%
|
3
+31%
|
4
+25%
|
7
+80%
|
15
+106%
|
20
+34%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(6)
|
(11)
|
(12)
|
(17)
|
(21)
|
(20)
|
(17)
|
(13)
|
(9)
|
(10)
|
(11)
|
(13)
|
(21)
|
(30)
|
(34)
|
(31)
|
(35)
|
(41)
|
(38)
|
(35)
|
|
| Selling, General & Administrative |
(1)
|
(6)
|
(9)
|
(12)
|
(14)
|
(14)
|
(10)
|
(7)
|
(4)
|
(6)
|
(6)
|
(7)
|
(18)
|
(27)
|
(31)
|
(34)
|
(37)
|
(38)
|
(35)
|
(31)
|
|
| Research & Development |
0
|
(5)
|
(2)
|
(3)
|
(5)
|
(5)
|
(4)
|
0
|
(2)
|
(2)
|
(3)
|
(3)
|
(1)
|
(1)
|
(1)
|
(0)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Depreciation & Amortization |
0
|
0
|
(2)
|
(2)
|
(2)
|
(1)
|
(3)
|
(3)
|
(3)
|
(2)
|
(3)
|
(3)
|
(2)
|
(2)
|
(3)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
5
|
4
|
0
|
0
|
0
|
|
| Operating Income |
(6)
N/A
|
(10)
-61%
|
(12)
-19%
|
(17)
-34%
|
(21)
-27%
|
(19)
+7%
|
(5)
+73%
|
(2)
+65%
|
(9)
-399%
|
(2)
+79%
|
(2)
-13%
|
(12)
-466%
|
(20)
-66%
|
(28)
-36%
|
(32)
-14%
|
(28)
+11%
|
(31)
-11%
|
(34)
-8%
|
(23)
+32%
|
(15)
+36%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(18)
|
7
|
(3)
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
1
|
0
|
(0)
|
(1)
|
(2)
|
(4)
|
(6)
|
|
| Non-Reccuring Items |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(18)
|
(18)
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(24)
N/A
|
(3)
+86%
|
(16)
-371%
|
(16)
-5%
|
(21)
-28%
|
(19)
+8%
|
(5)
+73%
|
(2)
+65%
|
(9)
-405%
|
(2)
+82%
|
(2)
-15%
|
(12)
-548%
|
(20)
-63%
|
(27)
-36%
|
(49)
-83%
|
(46)
+6%
|
(32)
+30%
|
(36)
-11%
|
(27)
+26%
|
(20)
+23%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
1
|
1
|
1
|
1
|
3
|
4
|
0
|
0
|
(1)
|
(1)
|
0
|
(1)
|
(0)
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
|
| Income from Continuing Operations |
(24)
|
(3)
|
(15)
|
(16)
|
(20)
|
(18)
|
(2)
|
2
|
(9)
|
(1)
|
(3)
|
(13)
|
(20)
|
(28)
|
(50)
|
(47)
|
(33)
|
(36)
|
(27)
|
(21)
|
|
| Income to Minority Interest |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(24)
N/A
|
(3)
+88%
|
(15)
-423%
|
(16)
-5%
|
(20)
-24%
|
(18)
+8%
|
(2)
+90%
|
2
N/A
|
(9)
N/A
|
(1)
+83%
|
(3)
-76%
|
(13)
-396%
|
(20)
-51%
|
(28)
-40%
|
(50)
-81%
|
(47)
+5%
|
(33)
+30%
|
(36)
-9%
|
(27)
+25%
|
(21)
+22%
|
|
| EPS (Diluted) |
-0.55
N/A
|
-0.03
+95%
|
-0.14
-367%
|
-0.15
-7%
|
-0.16
-7%
|
-0.15
+6%
|
-0.01
+93%
|
0.02
N/A
|
-0.07
N/A
|
-0.01
+86%
|
-0.02
-100%
|
-0.08
-300%
|
-0.09
-12%
|
-0.13
-44%
|
-0.21
-62%
|
-0.06
+71%
|
-0.05
+17%
|
-0.05
N/A
|
-0.03
+40%
|
-0.02
+33%
|
|